Q1 2024 Earnings Forecast for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Issued By Zacks Small Cap

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – Equities research analysts at Zacks Small Cap issued their Q1 2024 earnings per share (EPS) estimates for Brainstorm Cell Therapeutics in a note issued to investors on Thursday, April 11th. Zacks Small Cap analyst D. Bautz anticipates that the biotechnology company will earn ($0.07) per share for the quarter. The consensus estimate for Brainstorm Cell Therapeutics’ current full-year earnings is ($0.47) per share. Zacks Small Cap also issued estimates for Brainstorm Cell Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.07) EPS and FY2026 earnings at ($0.24) EPS.

Separately, StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics in a report on Wednesday, March 27th. They set a “sell” rating for the company.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI opened at $0.53 on Monday. The company has a 50-day simple moving average of $0.45 and a 200-day simple moving average of $0.31. The firm has a market capitalization of $36.02 million, a P/E ratio of -1.29 and a beta of 0.27. Brainstorm Cell Therapeutics has a 52 week low of $0.13 and a 52 week high of $3.37.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new stake in Brainstorm Cell Therapeutics in the 2nd quarter valued at $426,000. GTS Securities LLC acquired a new stake in Brainstorm Cell Therapeutics in the 3rd quarter valued at $41,000. Kingswood Wealth Advisors LLC acquired a new stake in Brainstorm Cell Therapeutics in the 1st quarter valued at $46,000. Marshall Wace LLP acquired a new stake in Brainstorm Cell Therapeutics in the 2nd quarter valued at $139,000. Finally, JPMorgan Chase & Co. increased its stake in Brainstorm Cell Therapeutics by 27.5% in the 1st quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock valued at $827,000 after buying an additional 53,036 shares during the last quarter. 14.33% of the stock is currently owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.